Upadacitinib Shows Promise for Hidradenitis Suppurativa | Docwire News
Treatment with the drug demonstrated lesion and pain control in moderate to severe disease.
Treatment with the drug demonstrated lesion and pain control in moderate to severe disease.
An analysis of chronic kidney disease (CKD) trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Read the latest research and news curated for nephrology videos.
The study will assess the overall response to olutasidenib plus azacitidine in higher-risk MDS, CMML, and advanced MPNs.
Several genetically predicted environmental factors increase the risk of IgA nephropathy (IgAN) and membranous nephropathy (MN), a study found.
A study found that combination cyclophosphamide and rituximab therapy for severe ANCA-associated vasculitis to minimize glucocorticoid use may reduce morbidity.
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgA nephropathy (IgAN), a study found.
Rajiv Agarwal, MBBS, discussed a study showing that a finerenone and empagliflozin combination has superior efficacy at reducing UACR in chronic kidney disease and type…
Dr. Richard Furie spoke with Nephrology Times about new data from the BLISS-LN study supporting the efficacy and safety of belimumab for active proliferative lupus…
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy (IgAN) to help with risk stratification.